These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions. O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822 [TBL] [Abstract][Full Text] [Related]
6. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Moffett RC; Patterson S; Irwin N; Flatt PR Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010 [TBL] [Abstract][Full Text] [Related]
7. Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation. Tanday N; Irwin N; Moffett RC; Flatt PR; O'Harte FPM Diabetes Obes Metab; 2020 Dec; 22(12):2468-2478. PubMed ID: 32844576 [TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085 [TBL] [Abstract][Full Text] [Related]
9. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice. O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054 [TBL] [Abstract][Full Text] [Related]
10. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice. Li Y; Zheng J; Shen Y; Li W; Liu M; Wang J; Zhu S; Wu M Med Sci Monit; 2018 May; 24():3293-3300. PubMed ID: 29777582 [TBL] [Abstract][Full Text] [Related]
11. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice. Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326 [TBL] [Abstract][Full Text] [Related]
12. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice. Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235 [TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765 [TBL] [Abstract][Full Text] [Related]
14. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Irwin N; Hunter K; Montgomery IA; Flatt PR Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064 [TBL] [Abstract][Full Text] [Related]
15. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. O'Harte FP; Franklin ZJ; Irwin N Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150 [TBL] [Abstract][Full Text] [Related]
16. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255 [TBL] [Abstract][Full Text] [Related]
17. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*. Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490 [TBL] [Abstract][Full Text] [Related]
18. Beneficial actions of the [A14K] analog of the frog skin peptide PGLa-AM1 in mice with obesity and degenerative diabetes: A mechanistic study. Musale V; Moffett RC; Conlon JM; Flatt PR; Abdel-Wahab YH Peptides; 2021 Feb; 136():170472. PubMed ID: 33338546 [TBL] [Abstract][Full Text] [Related]
19. Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes. Vasu S; Ojo OO; Moffett RC; Conlon JM; Flatt PR; Abdel-Wahab YHA Amino Acids; 2017 Oct; 49(10):1705-1717. PubMed ID: 28836148 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of the antidiabetic peptide [S4K]CPF-AM1 in db/db mice. Musale V; Moffett RC; Owolabi B; Conlon JM; Flatt PR; Abdel-Wahab YHA J Mol Endocrinol; 2021 Feb; 66(2):115-128. PubMed ID: 33252358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]